Dose-escalated cetuximab tolerated in colorectal cancer

July 5, 2012
Dose-escalated cetuximab tolerated in colorectal cancer
For patients with irinotecan-refractory metastatic colorectal cancer, dose escalation of cetuximab is well tolerated and may improve response and disease control rates, but patients experience more ≥grade 2 skin reactions, according to a study published online July 2 in the Journal of Clinical Oncology.

(HealthDay) -- For patients with irinotecan-refractory metastatic colorectal cancer (CRC), dose escalation of cetuximab is well tolerated and may improve response and disease control rates, but patients experience more grade ≥2 skin reactions, according to a study published online July 2 in the Journal of Clinical Oncology.

Eric Van Cutsem, M.D., Ph.D., of University Hospital Gasthuisberg in Leuven, Belgium, and colleagues investigated the effect of cetuximab dose escalation in 157 intent-to-treat patients with -refractory metastatic CRC. Following 21 days of standard-dose (400 mg/m² initial dose, then 250 mg/m² per week) treatment, participants who developed no or mild skin reactions (grade ≤1) at the standard dose were randomly allocated to standard-dose (45 patients) or dose-escalated (44 patients; up to 500 mg/m² per week) cetuximab. Patients with skin reactions grade ≥2 continued with standard-dose cetuximab and irinotecan.

The researchers found that the pharmacokinetic profiles were predictable across the dose range assessed. Cetuximab up to 500 mg/m² per week was well tolerated, with comparable grade 3 and 4 adverse events between the groups. There was an increase in grade ≥2 skin reactions for the dose-escalation versus the standard-dosing group (59 versus 38 percent). Although some evidence for improved response rate (30 versus 16 percent) and disease control rate (70 versus 58 percent) was noted with dose escalation, no overall survival benefit was found. with KRAS wild-type, compared with KRAS mutant tumors, had increased response rate with dose escalation versus standard dosing.

" serum concentrations increased predictably with dose. Higher dose levels were well tolerated," the authors write. "The possible indication for improved efficacy in the dose-escalation group warrants further investigation."

Several authors disclosed financial ties to pharmaceutical companies, including Merck KGaA, which funded the study.

More information: Abstract
Full Text (subscription or payment may be required)
Editorial

Related Stories

Low-dose CT noninferior for diagnosing appendicitis

April 26, 2012

(HealthDay) -- For young adults with suspected appendicitis, low-dose computed tomography (CT) is noninferior to standard-dose CT with respect to negative appendectomy rates, according to a study published in the April 26 ...

Chemo combination promising for multiple myeloma

May 2, 2012

(HealthDay) -- For patients with relapsed or refractory multiple myeloma, combination treatment with elotuzumab, lenalidomide, and low-dose dexamethasone is generally well tolerated, with encouraging response rates, according ...

ASCO: Dabrafenib/Trametinib active in metastatic melanoma

May 17, 2012

(HealthDay) -- For patients with V600 BRAF-mutant solid tumors, treatment with the oral BRAF inhibitor dabrafenib and the oral MEK 1/2 inhibitor trametinib is tolerated and has clinical activity in BRAF inhibitor-naive metastatic ...

Cannabinoid formulation benefits opioid-refractory pain

June 13, 2012

(HealthDay) -- A novel cannabinoid formulation, nabiximols, is safe and effective for patients with advanced cancer and opioid-refractory pain, especially at a low-dose, according to a study published in the May issue of ...

Recommended for you

Strange circular DNA may offer new way to detect cancers

July 30, 2015

Strange rings of DNA that exist outside chromosomes are distinct to the cell types that mistakenly produced them, researchers have discovered. The finding raises the tantalizing possibility that the rings could be used as ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.